Remdesivir use in Kidney Failure

Study at a Glance

Estimated Time Commitment

To be discussed

Eligibility

Hospitalized with COVID pneumonia, with evidence of reduced kidney function

Diagnosis Required

Confirmed COVID pneumonia diagnosis with evidence of reduced kidney function

Diseases Being Studied

SARS-CoV-2 related pneumonia
Location: San Antonio, TX

Primary Objective: To evaluate whether remdesivir (RDV, GS-5734™) reduces the composite risk of death or invasive mechanical ventilation (IMV) through Day 29 in participants with severely reduced kidney function who are hospitalized for coronavirus disease 2019 (COVID-19)

Study drugs: Remdesivir vs Placebo IV x 5 days

Eligible population: Hospitalized with COVID pneumonia, with evidence of reduced kidney function

Sample size: designed for 1116, however sponsor decided to close enrollment and stop the study due to low enrollment numbers study wide.

Local enrollment: 0, Close out visit scheduled for next week

Meet Your Clinical Research Team

Contact us

Principal Investigator: Local PI: Thomas Patterson, M.D.

For questions on this study, please contact Dr. Thomas Patterson